Nil-Rated Life-Saving Drugs: Cancer, HIV, TB, Rare Disease Schedule

A biosimilar oncology franchise closes its books on 30 September 2025 with the first eight days of the quarter having run at the old GST regime and the remaining 22 days having run under the 56th GST Council rate rationalisation that took effect on 22 September 2025. Its flagship trastuzumab biosimilar and its rituximab biosimilar have moved from the pre-22-September 5 percent output rate to a nil rate under the specified life-saving drug schedule. Its regular non-oncology formulations have moved from 12 percent to a harmonised 5 percent. Its diagnostic devices under HSN 9018 to 9022 have moved from 18 percent to 5 percent. The API it buys under HSN Chapter 29 stays at 5 percent. The aseptic packaging it buys under HSN 3923 and 4819 stays at 18 percent. The sterile fill-finish services and cold-chain logistics it buys stay at 18 percent. On the day of the cutover the finance team learns that the nil-rate benefit for the oncology portfolio is a Section 17(2) trigger, and every day of production of a nil-rated batch through common utilities and common capital equipment now pulls ITC into a Rule 42 or Rule 43 reversal that is added to output tax liability in GSTR-3B Table 4B(1). This is the reconciliation cascade behind life-saving drugs nil rate GST cancer HIV TB rare disease 22 September 2025, and the discipline that separates a producer with a clean quarter-end reconciliation from one that discovers the reversal shortfall in the following June’s annual Rule 42(2) true-up.

Quick reference

The reconciliation in one paragraph

A biosimilar oncology manufacturer that produces both nil-rated life-saving formulations (post-22-September-2025) and 5-percent regular formulations and 5-percent devices from the same plant is subject to Section 17(2) of the CGST Act 2017, which restricts input tax credit to the portion attributable to taxable supplies including zero-rated supplies. The nil-rated portion is an exempt supply for Section 17(2) purposes, and any ITC attributable to it must be reversed. Rule 42 handles inputs and input services — the period reversal is D1 = (E / F) x C2 where E is exempt-supply turnover, F is total turnover, and C2 is the common credit pool after excluding exclusive-use items. A separate D2 of 5 percent of C2 is added for notional non-business use. Rule 43 handles capital goods, amortising the common capital-goods credit at Tm = Tc / 60 over a 60-month useful life and applying the same (E / F) ratio to compute Te = (E / F) x Tm. D1 plus D2 plus Te is posted to GSTR-3B Table 4B(1) each period, and an annual reconciliation under Rule 42(2) redoes the ratio on year-end aggregates before the September following the year end. Section 54(3) inverted-duty refund is not available on the nil-rated output — that refund path is confined to inverted-rated taxable supplies, as established by the Supreme Court in Union of India v. VKC Footsteps India Pvt Ltd (2021) 10 SCC 674 and Rule 89(5) as amended by Notification 14/2022-Central Tax dated 5 July 2022. The reconciliation surface therefore has four independent axes: product-level output tax split, common credit segregation into T1 through T4 and C2, per-asset Rule 43 amortisation, and the monthly-to-annual Rule 42(2) true-up.

What the scenario looks like in India — a biosimilar oncology franchise persona

Indian biosimilar oncology producers operate a distinctive manufacturing footprint. The upstream biologics is produced through mammalian cell-line fermentation (typically Chinese Hamster Ovary or CHO expression systems) in bio-reactor trains ranging from 500 litre to 2,000 litre working volume. The downstream is a multi-step purification cascade — Protein A affinity chromatography, ion-exchange polishing, viral inactivation, sterile filtration — into a bulk drug substance. The bulk is transferred to a sterile fill-finish operation where it is filled into vials or pre-filled syringes in an ISO Class 5 aseptic environment, lyophilised where the formulation requires it, and secondary-packaged and labelled for the domestic market or exported.

Illustrative Indian biosimilar and oncology franchises operating at the scale relevant to this reconciliation include Biocon Biologics (the biosimilar subsidiary of Biocon Limited, with a portfolio spanning trastuzumab biosimilar CANMAb and rituximab biosimilar Reditux among others), Dr Reddy’s Laboratories (with a biosimilars franchise across trastuzumab, rituximab, and pegfilgrastim), Zydus Lifesciences (Cadila Healthcare, with an oncology and biosimilar programme through the Bengaluru and Ahmedabad clusters), Cipla (with the oncology franchise anchored by Cipla BioTec), Lupin (with biosimilar and oncology assets), and Natco Pharma (with the oncology generics franchise at the Kothur and Hyderabad plants). Aurobindo Pharma has built a biosimilar pipeline through its subsidiary programme and is a large formulator across the oncology and antiretroviral basket. In the antiretroviral therapy segment for HIV, Cipla and Aurobindo Pharma are historical anchors of the Indian ARV export franchise that also serves the domestic PMTCT and free-drug-programme supply. In the anti-tuberculosis segment, Lupin and Macleods Pharmaceuticals (unlisted) are historical anchors of the RNTCP and NTEP supply chain, with the four-drug fixed-dose combination for adult intensive-phase therapy as the flagship SKU. In the rare-disease segment, the specified schedule under the National Policy for Rare Diseases covers drugs used in the treatment of Gaucher disease, Pompe disease, Fabry disease, and other lysosomal storage disorders where enzyme replacement therapy is the standard of care — imported by several distributors and manufactured domestically for a small subset.

The illustrative persona for this article is a biosimilar oncology franchise at the scale that a leading Indian biosimilar producer runs — approximately Rs 1,100 crore of annual portfolio revenue across a trastuzumab biosimilar equivalent to a CANMAb-style product, a rituximab biosimilar equivalent to a Reditux-style product, and a supporting basket of oncology formulations. The manufacturing operation runs a Bengaluru or Bommasandra bio-reactor train plus a dedicated sterile fill-finish line for the biosimilar output, and it shares utility infrastructure (water-for-injection plant, HVAC, clean-room complex) with the regular formulation lines that also run through the same plant. It is that shared utility and clean-room footprint that pulls the entire manufacturing operation into the common credit pool for Rule 42 and Rule 43 purposes.

The regulatory overlay — Section 17(2) CGST, Rule 42, Rule 43, and the distinction from Section 54(3)

Four regulatory anchors govern the post-22-September-2025 reconciliation for a nil-rated life-saving drug manufacturer, and each has an operational consequence that must be modelled before the cutover.

Section 17(2) of the CGST Act 2017 is the statutory anchor. Where goods or services are used partly for effecting taxable supplies (including zero-rated supplies to export or SEZ) and partly for effecting exempt supplies, the ITC is restricted to the portion attributable to the taxable supplies. Exempt supply for this purpose is defined in Section 2(47) to include nil-rated supply. A nil-rated life-saving drug output is therefore an exempt supply for the ITC restriction, notwithstanding that the customer pays no GST on the invoice.

Rule 42 of the CGST Rules 2017 operationalises the input and input-services reversal. The period reversal formula is D1 = (E / F) x C2. E is the aggregate value of exempt supplies during the tax period; F is the total turnover in the State; C2 is the common credit — the input tax credit remaining after subtracting T1 (used exclusively for non-business), T2 (used exclusively for exempt supplies), T3 (blocked credits under Section 17(5)), and T4 (used exclusively for taxable supplies including zero-rated). A separate D2 of 5 percent of C2 is added for notional non-business use. D1 plus D2 is added to output tax liability in GSTR-3B Table 4B(1) for the month. An annual reconciliation under Rule 42(2) redoes the ratio on year-end aggregates and adjusts the interim monthly reversals up or down; the annual reconciliation is filed before the September following the financial year end.

Rule 43 of the CGST Rules 2017 handles capital goods separately because capital goods have a useful life that spans multiple periods. Capital goods used exclusively for exempt supplies get no ITC at all at purchase; capital goods used exclusively for taxable supplies get full ITC; capital goods that will be used commonly for both — the sterile fill-finish line that processes both a nil-rated oncology biosimilar and a 5-percent regular formulation, the aseptic packaging line, the utility infrastructure — get their credit into a common pool amortised over a useful life of 60 months. Tm = Tc / 60 and Te = (E / F) x Tm are the monthly amortised credit and the exempt-attributable reversal respectively. Te is added to GSTR-3B Table 4B(1) alongside the Rule 42 D1 plus D2 figure.

Section 54(3) of the CGST Act 2017 and Rule 89(5) as amended by Notification 14/2022-Central Tax dated 5 July 2022 govern the inverted-duty refund, but critically only for inverted-rated taxable output supplies. A nil-rated output is not an inverted-rated taxable output — it is an exempt output. The Section 54(3) refund path is therefore not available on the nil-rated portion of the portfolio. Producers cannot claim a Section 54(3) refund on ITC attributable to the life-saving drug output; that ITC is reversed under Rule 42 and Rule 43, not refunded. The 5-percent regular formulations and 5-percent devices remain eligible for the Section 54(3) inverted-duty refund on the taxable portion of the portfolio, because the 5-percent output rate against the 18-percent packaging and services input rate still produces an inversion — see the Rule 89(5) inverted-duty refund pharma formulations complete guide for that adjacent path.

A worked example — a Biocon-scale biosimilar oncology franchise at monthly close

Illustrative — the following figures represent the operating pattern of a biosimilar oncology franchise of the scale that a leading Indian biosimilar producer runs. Public disclosures do not reveal per-SKU input tax breakdown or common-credit segregation detail; cross-verify against your own GSTR-1 and GSTR-2B feed and your capital-goods register before action.

A biosimilar oncology franchise closes the month of October 2025 (the first full month under the post-22-September-2025 regime) with a portfolio annualised at approximately Rs 1,100 crore of revenue. The monthly turnover breakdown across product categories is:

The input tax credit for the same month, before segregation:

Segregating the aggregate T into the Rule 42 components:

• T1 (exclusive non-business) — nil
• T2 (exclusive to exempt — dedicated API lots for the oncology biosimilar, dedicated printed cartons for the oncology SKUs) — Rs 0.90 crore (part of the API ITC and part of the packaging ITC allocable to the oncology-dedicated batches)
• T3 (blocked under Section 17(5)) — nil for this profile
• T4 (exclusive to taxable including zero-rated) — Rs 0.20 crore (allocable to the regular formulation-dedicated runs)
• C1 = T − T1 − T2 − T3 = 2.964 − 0.90 − 0 − 0 = Rs 2.064 crore
• C2 = C1 − T4 = 2.064 − 0.20 = Rs 1.864 crore

The Rule 42 reversal for October:

• D1 = (E / F) x C2 = 0.7556 x 1.864 = Rs 1.408 crore
• D2 = 5 percent of C2 = 0.05 x 1.864 = Rs 0.093 crore
• D1 + D2 = Rs 1.501 crore

The Rule 43 capital-goods reversal for the same month, taking a Rs 60 crore aggregate common capital-goods ITC pool (bio-reactor train, sterile fill-finish line, aseptic packaging line, utility infrastructure — a representative pool for a plant of this scale, amortised across the mixed product portfolio):

• Tc = Rs 60 crore
• Tm = Tc / 60 = Rs 1.0 crore per month
• Te = (E / F) x Tm = 0.7556 x 1.0 = Rs 0.756 crore

Total October reversal posting to GSTR-3B Table 4B(1) = D1 + D2 + Te = Rs 2.257 crore. Plus the T2 reversal of Rs 0.90 crore (which is a direct reversal, not a proportionate reversal — the ITC on inputs used exclusively for exempt supplies is fully reversed as T2 and is not netted into C2 at all). Aggregate ITC impact from the exempt-supply cascade for October = Rs 3.157 crore against the aggregate ITC available of Rs 2.964 crore — the reversal exceeds the collectible ITC because the T2 component was never eligible in the first place and the Rule 43 amortisation is a cash-neutral timing adjustment against the historical capital-goods purchase.

Annualising the October pattern across 12 months, and allowing for seasonality in the API and packaging procurement cycle, the biosimilar oncology franchise faces a Rule 42 plus Rule 43 reversal exposure in the range of Rs 40 to Rs 60 crore per year on the nil-rated life-saving portfolio. This is the counterintuitive cost of the life-saving nil-rate benefit for the producer — the input tax paid on API, packaging, sterile fill-finish services, and capital goods flows through to a common-credit reversal rather than a Section 54(3) refund path. The annual Rule 42(2) reconciliation before the September following the financial year end redoes the ratio on year-end aggregates and produces the interim-to-annual variance line that the finance team files as an adjustment in the September GSTR-3B.

Common reconciliation breakages

Five breakages recur across biosimilar and oncology manufacturers that transitioned to the post-22-September-2025 nil-rated schedule, and each maps to a specific control failure.

• Treating the nil-rate output as zero-rated. Zero-rated supply under Section 16 of the IGST Act 2017 preserves the ITC entitlement — an exporter or SEZ supplier claims full ITC and either uses it against domestic taxable output or claims a Section 54 refund. A nil-rated supply is not zero-rated — it is exempt for Section 17(2) purposes. Manufacturers that mis-treat the nil-rate output as zero-rated retain the full ITC and fail to file the Rule 42 or Rule 43 reversal, exposing themselves to Section 73 or Section 74 demand notices at the departmental audit and to interest under Section 50.

• Under-reversal at interim months and shock true-up at annual Rule 42(2). The monthly Rule 42 reversal is computed on the period’s E and F. Where the period turnover mix is unrepresentative of the year (a plant that ran a heavy campaign on the regular formulations in one month and a heavy campaign on the nil-rated oncology biosimilar in another), the interim reversal is out of alignment with the annual reversal. Rule 42(2) then requires a true-up in the September following the year end — often a shock adjustment that reveals the finance team has been under-reversing for eight or nine months. Reconciliation discipline: run the Rule 42 model on a rolling 12-month E/F ratio for interim posting purposes and reconcile against the actual period ratio only for the audit trail.

• Failing to segregate T2 from C2 correctly. T2 is the ITC on inputs used exclusively for exempt supplies — dedicated API lots for the oncology biosimilar, oncology-branded printed cartons, oncology-dedicated printed inserts. That ITC is fully reversed as T2 and never enters the common pool. Producers that dump all input ITC into C2 without segregating T2 first end up computing a proportionate reversal on inputs that should have been fully reversed, and they under-reverse the exempt exposure. The reconciliation discipline is a per-batch input consumption bridge from the manufacturing execution system into the ITC ledger that tags each input lot as exclusive-taxable, exclusive-exempt, or common.

• Ignoring Rule 43 on the fill-finish and clean-room capital-goods pool. Rule 43 is easier to miss than Rule 42 because capital goods are usually treated as a one-time ITC event at purchase. The 60-month amortisation and the monthly Te = (E / F) x Tm reversal is a discipline the plant finance team has to build into the fixed-asset register. Missed Rule 43 reversals compound month over month and surface as a large aggregate demand at the annual audit.

• Attempting a Section 54(3) refund on the nil-rated output. The Section 54(3) refund path is confined to inverted-rated taxable supplies. The Rule 89(5) formula, the Notification 14/2022 amendment, and the Union of India v. VKC Footsteps line of authority all operate on taxable output supplies. Nil-rated life-saving drug output is exempt, not inverted-rated taxable. Refund claims filed against nil-rated output turnover are rejected by the proper officer, and repeated filings can trigger a departmental review of the entire refund history. The correct treatment path is Rule 42 plus Rule 43 reversal, not a Section 54(3) refund.

How a reconciliation platform handles this

A purpose-built pharma reconciliation platform ingests the GSTR-1 outward supply register split by HSN and rate, the GSTR-2B inward supply register, the fixed-asset register with capital-goods ITC amounts, the manufacturing execution system’s per-batch input consumption bridge, and the DPCO and NLEM scheduled-formulation ceiling-price register — and produces a per-period common-credit reversal pack. The platform computes E and F on the outward supply feed each period, segregates the ITC into T1 through T4 and C2 using the per-batch bridge to identify exclusive-use inputs, produces D1 = (E/F) x C2 and D2 = 0.05 x C2 for the Rule 42 posting, carries every common-use capital-goods asset in a 60-month amortisation schedule and posts Te = (E/F) x Tm for the Rule 43 leg, reconciles the aggregate D1 + D2 + Te against GSTR-3B Table 4B(1), and rolls the whole picture forward to the annual Rule 42(2) true-up. A match rate improvement from 51 percent to 88 percent on the input-to-batch attribution, combined with an ISO 27001:2022 posture and DPDP Act 2023 aligned data handling, is what makes the platform an infrastructure investment for a biosimilar or oncology producer at the Rs 1,100 crore portfolio scale rather than a spreadsheet substitute.

Cross-cluster bridges and where to read next

The nil-rate life-saving schedule sits inside the wider 56th GST Council pharma rate rationalisation package. For the umbrella pharma transition from the old regime to the harmonised 5-percent rate on non-life-saving drugs and the medical device shift from 18 percent to 5 percent, read the 56th GST Council pharma drugs and medical devices 5 percent transition walkthrough. For the operational discipline on inventory that straddles the 22 September 2025 cutover — batches manufactured under the old rate but invoiced under the new rate — the Pharma inventory GST rate switch 22 September 2025 reconciliation article covers the Section 15 time-of-supply mechanics. For the Council’s own FAQ acknowledgement of the deepened inverted duty on the taxable 5-percent output leg and the nil-rate reversal exposure, read the GST Council FAQ Q10, Q25, Q51 pharma clarifications reading guide walkthrough. For the adjacent Section 54(3) refund path on the 5-percent taxable output — which is the path that a producer without a nil-rated portfolio uses to recover the inverted-duty accumulation — the Rule 89(5) inverted-duty refund pharma formulations complete guide article covers the amended Net ITC formula and the RFD-01 workflow.

The Section 17(2) common credit reversal mechanic in this article shares its statutory grammar with the edible-oil sector, where Notification 09/2022-Central Tax (Rate) dated 13 July 2022 barred the Section 54(3) inverted-duty refund on HSN Chapter 15 supplies — the two are different mechanics (nil-rate reversal versus statutory refund block) with a shared underlying question of “what happens when input tax accumulation cannot be refunded?” The Edible oil Chapter 15 IDR refund blocked under Notification 09/2022 walkthrough covers the sister mechanic. For the methodology framework that a pharma finance team uses to instrument this reconciliation surface, see the Reconciliation Failure Mode Analysis design pillar and the Reconciliation Playbook monthly close operations pillar — Terra Insight’s own branded frameworks for the design layer and the operations layer of a reconciliation build. The commercial pillar for the pharma cluster is Pharma reconciliation software India; the umbrella authority is reconciliation software India.

The five FAQs below address the operational questions Indian biosimilar and oncology producer controllers ask most often when modelling the Section 17(2) plus Rule 42 plus Rule 43 reversal cascade against the post-22-September-2025 nil-rated life-saving drug schedule.

Terra Insight Editorial Team Reconciliation Infrastructure

Content authored by practitioners with experience at Amazon India, Intuit QuickBooks, and the Tata Group. Meet the team →

Published 13 July 2026

Domain expertise

TDS Reconciliation GST Input Credit Platform Settlements NACH Batch Matching Bank Reconciliation Form 26AS Matching ERP Integrations Enterprise Finance Ops

Reviewed by

NK

Navin Krishnan

Managing Director & Founder — Terra Insight

Ex Amazon India · Intuit QuickBooks · Tata nexarc

ISO 27001:2022 Patent Pending Incorporated 2024